Publicaciones en las que colabora con Vicente Germán Casabó Alós (36)

2016

  1. Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 41, Núm. 6, pp. 795-806

2015

  1. Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

    European Journal of Pharmaceutical Sciences, Vol. 74, pp. 86-94

  2. Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients

    European Journal of Pharmaceutical Sciences, Vol. 73, pp. 57-63

  3. Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers

    Journal of Pharmacological and Toxicological Methods, Vol. 71, pp. 21-32

2014

  1. Modified nonsink equation for permeability estimation in cell monolayers: Comparison with standard methods

    Molecular Pharmaceutics, Vol. 11, Núm. 5, pp. 1403-1414

2013

  1. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier

    Molecular Pharmaceutics, Vol. 10, Núm. 10, pp. 3822-3831

  2. Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract

    Xenobiotica, Vol. 43, Núm. 9, pp. 745-754

2011

  1. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat

    Drug Metabolism and Disposition, Vol. 39, Núm. 2, pp. 294-301

  2. Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model

    European Journal of Pharmaceutical Sciences, Vol. 42, Núm. 3, pp. 290-299

2008

  1. Correlación entre modelos in vitro, in situ e in vivo en estudios de absorción

    Revista Médicas UIS, Vol. 21, Núm. 1

  2. Correlation Between In Vitro, In Situ, and In Vivo Models

    Biosimulation in Drug Development (Wiley-VCH Verlag GmbH & Co. KGaA), pp. 87-113

2007

  1. Bioavailability and pharmacokinetic model for ritonavir in the rat

    Journal of Pharmaceutical Sciences, Vol. 96, Núm. 3, pp. 633-643

  2. Population modelling to describe pharmacokinetics of amiodarone in rats: Relevance of plasma protein and tissue depot binding

    European Journal of Pharmaceutical Sciences, Vol. 30, Núm. 2, pp. 190-197

2006

  1. Estudio de la interaccion entre Ritonavir y Saquinavir en su absorción intestinal

    Ciencia y Tecnologia Pharmaceutica, Vol. 16, Núm. 1, pp. 17-21

  2. Estudio de la interacción entre ritonavir y saquinavir en su absorción intestinal

    Ciencia y tecnología pharmacéutica: Revista española del medicamento y del producto sanitario, Vol. 16, Núm. 1, pp. 17-21

  3. Labetalol absorption kinetics: Rat small intestine and colon studies

    Journal of Pharmaceutical Sciences, Vol. 95, Núm. 8, pp. 1733-1741

  4. Modelling intestinal absorption of salbutamol sulphate in rats

    International Journal of Pharmaceutics, Vol. 314, Núm. 1, pp. 21-30

2005

  1. Use of nonlinear mixed effect modeling for the intestinal absorption data: Application to ritonavir in the rat

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 61, Núm. 1-2, pp. 20-26

2004

  1. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime

    European Journal of Pharmaceutical Sciences, Vol. 21, Núm. 2-3, pp. 217-223

2002

  1. Intestinal transport of cefuroxime axetil in rats: Absorption and hydrolysis processes

    International Journal of Pharmaceutics, Vol. 234, Núm. 1-2, pp. 101-111